Pfizer
As of the edition of 20 October 2026, Pfizer runs 892 drugs, 463 of them marketed; it is on route A at 84 targets and on route B at 102 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 54 company names in this family.
- Lederle Laboratories: acquired in 1994; successor Wyeth
- G D Searle: acquired in 2003; successor Pfizer Inc.
- Gd Searle Llc: acquired in 2003; successor Pfizer Inc.
- Pharmacia: acquired in 2003; successor Pfizer Inc.
- Pharmacia and Upjohn: acquired in 2003; successor Pfizer Inc.
- Pharmacia & Upjohn Company LLC: acquired in 2003; successor Pfizer Inc.
- Mayne Pharma Llc: acquired in 2007; successor Pfizer Inc.
- Encysive Pharmaceuticals: acquired in 2008; successor Pfizer Inc.
- Wyeth: acquired in 2009; successor Pfizer Inc.
- Wyeth Ayerst Laboratories: acquired in 2009; successor Pfizer Inc.
- Wyeth Ayerst Research: acquired in 2009; successor Pfizer Inc.
- Wyeth Consumer Healthcare: acquired in 2009; successor Pfizer Inc.
And 14 more.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 463 |
| Active | 56 |
| Went quiet | 148 |
| Stopped | 193 |
| Withdrawn from market | 7 |
| Status not established | 25 |
| Total | 892 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paclitaxel | none listed | 0 |
| Cisplatin | none listed | 0 |
| Carboplatin | none listed | 0 |
| Gemcitabine | none listed | 1 |
| Bevacizumab | Ends 2027 (orphan exclusivity) | 2 |
| Rituximab | Ends 2028 (orphan exclusivity) | 1 |
| Docetaxel anhydrous | none listed | 0 |
| Fluorouracil | none listed | 2 |
| Doxorubicin | none listed | 3 |
| Oxaliplatin | none listed | 0 |
| Prednisone | none listed | 1 |
| Irinotecan | none listed | 2 |
| Methotrexate | none listed | 2 |
| Cytarabine | none listed | 0 |
| Leucovorin | none listed | 0 |
| Dexmedetomidine | none listed | 9 |
| Bupivacaine | none listed | 1 |
| Filgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Lidocaine | none listed | 2 |
| Pemetrexed | none listed | 7 |
| Vincristine | none listed | 0 |
| Trastuzumab | Ended 2017 (orphan exclusivity) | 0 |
| Bortezomib | none listed | 1 |
| Ketamine | none listed | 10 |
| Midazolam | none listed | 1 |
A route B row is one company at one target. 438 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 84 targets, route B at 102 targets.
All 186 rows on route A or B
In the product186 company-target rows on route A or B; 183 are not shown here, and no score is.
See all 186 targets where Pfizer needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 656 trials led
- Skin and connective tissue: 377 trials led
- Immune system: 345 trials led